Michael Crowley - 14 Mar 2025 Form 4 Insider Report for BIO-RAD LABORATORIES, INC. (BIO BIO.B)

Role: EVP, GBL Commercial Operations
Signature: /s/ Michael Crowley
Issuer symbol: BIO BIO.B
Transactions as of: 14 Mar 2025
Net transactions value: -$263,224
Form type: 4
Filing time: 18 Mar 2025, 16:36:38 UTC
Previous filing: 10 Sep 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BIO BIO.B	Bio-Rad A Common Stock	Options Exercise	$477,960	+3,000	+37%	$159.32	11,171	14 Mar 2025	Direct
transaction	BIO BIO.B	Bio-Rad A Common Stock	Sale	$741,184	-3,000	-27%	$247.06	8,171	14 Mar 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BIO BIO.B	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-3,000	-100%	$0.000000	0	14 Mar 2025	Bio-Rad A Common Stock	3,000	$159.32	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.0239 to $249.1550, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2	The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 7, 2017, which was the first anniversary of the date on which the option was granted.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.0239 to $249.1550, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 7, 2017, which was the first anniversary of the date on which the option was granted.